The effect of variable cigarette consumption on the interaction with clozapine and olanzapine

被引:131
作者
Haslemo, Tore
Eikeseth, Per Haakon
Tanum, Lars
Molden, Espen
Refsum, Helge
机构
[1] Daikonhjemmet Hosp, Dept Psychopharmacol, N-0319 Oslo, Norway
[2] Lovisenberg Hosp, Dept Psychiat, Oslo, Norway
关键词
smoking; clozapine; olanzapine;
D O I
10.1007/s00228-006-0209-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective Cigarette smoking has been shown in several studies to induce the metabolism of the cytochrome P4501A2 (CYP1A2) substrates clozapine and olanzapine. The aim of the present study was to investigate the dose-dependent effect of cigarette smoking on serum concentrations of these drugs in a naturalistic setting. Methods In 73 schizophrenic patients recruited from psychiatric nursing homes, patient characteristics, smoking habits, drug dosing and serum concentrations of clozapine (n=33) and olanzapine (n=40) were registered. Concentration to dose (C/D) ratios of clozapine and olanzapine in non-smokers and subgroups of smokers were compared. Results Fifty-nine patients (80%) were smokers and these were stratified into the following groups according to smoking habits: 1-6 (n=0), 7-12 (n=13), 13-19 (n=18) and >= 20 (n=28) cigarettes daily. While the mean ratio was twice as high in non-smokers compared to smokers for both drugs (p < 0.01), the C/D ratios of clozapine and olanzapine were not significantly different between the subgroups of smokers (p > 0.15). Absolute serum concentrations were also higher in non-smokers compared to smokers: 50% for clozapine (p=0.058) and 67% for olanzapine (p < 0.01). Conclusion A daily consumption of 7-12 cigarettes is probably sufficient for maximum induction of clozapine and olanzapine metabolism. A 50% lower starting dose of both drugs in non-smokers seems rational to avoid side effects.
引用
收藏
页码:1049 / 1053
页数:5
相关论文
共 25 条
[1]   Sex differences in the risk of schizophrenia - Evidence from meta-analysis [J].
Aleman, A ;
Kahn, RS ;
Selten, JP .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (06) :565-571
[2]   Therapeutic monitoring of psychotropic drugs -: An outline of the AGNP-TDM Expert Group Consensus Guideline [J].
Baumann, P ;
Hiemke, C ;
Ulrich, S ;
Rao, GML ;
Eckermann, G ;
Gerlach, M ;
Kuss, HJ ;
Laux, G ;
Müller-Oerlinghausen, B ;
Rieder, P ;
Zernig, G .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :167-170
[3]   Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients [J].
Bondolfi, G ;
Morel, F ;
Crettol, SV ;
Rachid, F ;
Baumann, P ;
Eap, CB .
THERAPEUTIC DRUG MONITORING, 2005, 27 (04) :539-543
[4]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[5]   Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine [J].
Carrillo, JA ;
Herráiz, AG ;
Ramos, SI ;
Gervasini, G ;
Vizcaíno, S ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) :119-127
[6]   A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors [J].
de Leon, J ;
Diaz, FJ .
SCHIZOPHRENIA RESEARCH, 2005, 76 (2-3) :135-157
[7]   Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication [J].
Gex-Fabry, M ;
Balant-Gorgia, AE ;
Balant, LP .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :46-53
[8]  
KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
[9]  
Khan Ahsan Y, 2005, J Psychiatr Pract, V11, P289, DOI 10.1097/00131746-200509000-00003
[10]   SMOKING AND SCHIZOPHRENIA [J].
LOHR, JB ;
FLYNN, K .
SCHIZOPHRENIA RESEARCH, 1992, 8 (02) :93-102